Reported 12 months ago
Pfizer's stock has been underperforming, with only 4 out of the past 10 years seeing it outperform the S&P 500, mostly aided by its COVID vaccine. Facing patent cliffs and revenue challenges, Pfizer's future remains uncertain despite its low valuation. The company's focus on cancer treatments and potential revenue drops from multiple top drugs present risks. While Pfizer may have new products in its pipeline by 2030, it could still end up as a no-growth stock. Investors considering Pfizer stock will have to weigh these factors alongside its 6% dividend yield.
Source: YAHOO